Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Hiroyuki Futani

Showing results (41-50 of 49) with videos related to

Pageof 5
Sort By:
You have reached the last page of results.This site can display upto 49 results.
Journal of Cancer Research and Clinical Oncology|December 11, 2008
Sodium valproate, a histone deacetylase inhibitor, decreases the secretion of soluble Fas by human osteosarcoma cells and increases their sensitivity to Fas-mediated cell deathKoji Yamanegi, Junko Yamane, Masaki Hata, et al.
Oncology Reports|August 28, 2012
Downregulation of matrix metalloproteinase-9 mRNA by valproic acid plays a role in inhibiting the shedding of MHC class I-related molecules A and B on the surface of human osteosarcoma cellsKoji Yamanegi, Junko Yamane, Kenta Kobayashi, et al.
In Vivo (Athens, Greece)|June 27, 2023
Clinical Utility of Bland Embolization Using Microspheres for Painful Malignant Musculoskeletal TumorsJunichi Taniguchi, Haruyuki Takaki, Hiroshi Kodama, et al.
Journal of Interferon & Cytokine Research : the Official Journal of the International Society for Interferon and Cytokine Research|March 24, 2004
Inhibition by interleukin-18 of the growth of Dunn osteosarcoma cellsTakuya Okamoto, Naoko Yamada, Tohru Tsujimura, et al.
International Journal of Oncology|May 12, 2012
Valproic acid cooperates with hydralazine to augment the susceptibility of human osteosarcoma cells to Fas- and NK cell-mediated cell deathKoji Yamanegi, Junko Yamane, Kenta Kobayashi, et al.
Clinical Orthopaedics and Related Research|April 17, 2020
What Factors Are Associated with Treatment Outcomes of Japanese Patients with Clear Cell Chondrosarcoma?Robert Nakayama, Keiko Hayakawa, Eisuke Kobayashi, et al.
Oncology Reports|November 3, 2010
Sodium valproate, a histone deacetylase inhibitor, augments the expression of cell-surface NKG2D ligands, MICA/B, without increasing their soluble forms to enhance susceptibility of human osteosarcoma cells to NK cell-mediated cytotoxicityKoji Yamanegi, Junko Yamane, Kenta Kobayashi, et al.
Cancer Science|October 24, 2007
Enhanced suppression of pulmonary metastasis of malignant melanoma cells by combined administration of alpha-galactosylceramide and interleukin-18Shoji Nishio, Naoko Yamada, Hideki Ohyama, et al.
Pathology International|July 2, 2015
Primary central chondrosarcoma of long bone, limb girdle and trunk: Analysis of 174 cases by numerical scoring on histologyEiichi Konishi, Yasuaki Nakashima, Masayuki Mano, et al.
Pageof 5

Showing results (41-50 of 49) with videos related to

Sort By:
Pageof 5
You have reached the last page of results.This site can display upto 49 results.
Journal of Cancer Research and Clinical Oncology|December 11, 2008
Sodium valproate, a histone deacetylase inhibitor, decreases the secretion of soluble Fas by human osteosarcoma cells and increases their sensitivity to Fas-mediated cell deathKoji Yamanegi, Junko Yamane, Masaki Hata, et al.
Oncology Reports|August 28, 2012
Downregulation of matrix metalloproteinase-9 mRNA by valproic acid plays a role in inhibiting the shedding of MHC class I-related molecules A and B on the surface of human osteosarcoma cellsKoji Yamanegi, Junko Yamane, Kenta Kobayashi, et al.
In Vivo (Athens, Greece)|June 27, 2023
Clinical Utility of Bland Embolization Using Microspheres for Painful Malignant Musculoskeletal TumorsJunichi Taniguchi, Haruyuki Takaki, Hiroshi Kodama, et al.
Journal of Interferon & Cytokine Research : the Official Journal of the International Society for Interferon and Cytokine Research|March 24, 2004
Inhibition by interleukin-18 of the growth of Dunn osteosarcoma cellsTakuya Okamoto, Naoko Yamada, Tohru Tsujimura, et al.
International Journal of Oncology|May 12, 2012
Valproic acid cooperates with hydralazine to augment the susceptibility of human osteosarcoma cells to Fas- and NK cell-mediated cell deathKoji Yamanegi, Junko Yamane, Kenta Kobayashi, et al.
Clinical Orthopaedics and Related Research|April 17, 2020
What Factors Are Associated with Treatment Outcomes of Japanese Patients with Clear Cell Chondrosarcoma?Robert Nakayama, Keiko Hayakawa, Eisuke Kobayashi, et al.
Oncology Reports|November 3, 2010
Sodium valproate, a histone deacetylase inhibitor, augments the expression of cell-surface NKG2D ligands, MICA/B, without increasing their soluble forms to enhance susceptibility of human osteosarcoma cells to NK cell-mediated cytotoxicityKoji Yamanegi, Junko Yamane, Kenta Kobayashi, et al.
Cancer Science|October 24, 2007
Enhanced suppression of pulmonary metastasis of malignant melanoma cells by combined administration of alpha-galactosylceramide and interleukin-18Shoji Nishio, Naoko Yamada, Hideki Ohyama, et al.
Pathology International|July 2, 2015
Primary central chondrosarcoma of long bone, limb girdle and trunk: Analysis of 174 cases by numerical scoring on histologyEiichi Konishi, Yasuaki Nakashima, Masayuki Mano, et al.
Pageof 5